These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 21820319

  • 1. Increases in body mass index during infliximab therapy in patients with Crohn's disease: an open label prospective study.
    Nakahigashi M, Yamamoto T.
    Cytokine; 2011 Nov; 56(2):531-5. PubMed ID: 21820319
    [Abstract] [Full Text] [Related]

  • 2. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O, Bascietto C, Viola F, Bueno de Mesquita M, Barbato M, Mancini V, Bosco S, Cucchiara S.
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
    Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Travers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R, REACH Study Group.
    Gastroenterology; 2007 Mar; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I.
    Reinisch W, Wang Y, Oddens BJ, Link R.
    Aliment Pharmacol Ther; 2012 Mar; 35(5):568-76. PubMed ID: 22251435
    [Abstract] [Full Text] [Related]

  • 10. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q, Hogezand RA, Lamers CB, Verspaget HW.
    Aliment Pharmacol Ther; 2004 Sep 01; 20(5):585-92. PubMed ID: 15339330
    [Abstract] [Full Text] [Related]

  • 11. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study.
    Asteria CR, Ficari F, Bagnoli S, Milla M, Tonelli F.
    Scand J Gastroenterol; 2006 Sep 01; 41(9):1064-72. PubMed ID: 16938720
    [Abstract] [Full Text] [Related]

  • 12. Infliximab therapy in Crohn's disease: a pragmatic approach?
    Kevans D, Keegan D, Mulcahy HE, O'Donoghue DP.
    Aliment Pharmacol Ther; 2006 Jul 15; 24(2):351-9. PubMed ID: 16842462
    [Abstract] [Full Text] [Related]

  • 13. [Therapeutic effects of combined enteral nutrition with Tripterygium Wilfordii poly-glycoside in remission induction of active adult Crohn's disease].
    Gong JF, Niu LY, Wei XW, Zhu WM, Li N, Li JS.
    Zhonghua Wai Ke Za Zhi; 2009 Aug 15; 47(16):1213-7. PubMed ID: 19781164
    [Abstract] [Full Text] [Related]

  • 14. The prevalence of malnutrition and the evolution of nutritional status in patients with moderate to severe forms of Crohn's disease treated with Infliximab.
    Vadan R, Gheorghe LS, Constantinescu A, Gheorghe C.
    Clin Nutr; 2011 Feb 15; 30(1):86-91. PubMed ID: 20719413
    [Abstract] [Full Text] [Related]

  • 15. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
    Sandborn WJ, Hanauer SB.
    Am J Gastroenterol; 2002 Dec 15; 97(12):2962-72. PubMed ID: 12492177
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
    Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P.
    N Engl J Med; 2003 Feb 13; 348(7):601-8. PubMed ID: 12584368
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn's disease patients.
    Kane SV, Chao J, Mulani PM.
    Adv Ther; 2009 Oct 13; 26(10):936-46. PubMed ID: 19838649
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.